Total Funding
4
22
Total FundingSeries D raised
Growth Score 4 in past quarter
-7 pts
Heat Score 22 in past quarter
-1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
408629
Ceregene is a biotechnology company that treats neurodegenerative disorders using the delivery of nervous system growth factors.
- Stephen Sherwin: Co-Founder & ChairmanPast Role: Genentech, Vice President of Clinical Research
- Arpesh Mehta: Senior Research AssociatePast Role: Black River Asset Management, Director
About the Company
Ceregene is a private, San Diego-based biotechnology company focused on the treatment of major neurodegenerative disorders using the delivery of nervous system growth factors. Their clinical programs include CERE-110, an AAV2 based vector expressing nerve growth factor, which is about to enter Phase 2 studies for the treatment of Alzheimer's
disease, and CERE-120, which recently completed a Phase 2 trial in Parkinson's disease and is currently being evaluated for future development. CERE-135 and CERE-140 are in preclinical development for amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) and ocular diseases, respectively.


